# Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

> **NCT00897676** · PHASE1,PHASE2 · COMPLETED · sponsor: **Diva De Leon** · enrollment: 17 (actual)

## Conditions studied

- Congenital Hyperinsulinism

## Interventions

- **DRUG:** Exendin-(9-39)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00897676
- **Lead sponsor:** Diva De Leon
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2016-08-26
- **Final completion:** 2017-01
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00897676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00897676, "Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00897676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*